Comparison of anaphylactic reactions to asparaginase derived fromEscherichia coli and fromErwinia culturs
- 1 October 1976
- Vol. 38 (4), 1843-1846
- https://doi.org/10.1002/1097-0142(197610)38:4<1843::aid-cncr2820380463>3.0.co;2-j
Abstract
A retrospective study was undertaken comparing the frequency and severity of anaphylactic reactions to E. coli-derived and Erwinia-derived asparaginase given intravenously on a weekly dosage schedule. Both drugs were found to produce life-threatening hypersensivity reactions with the chance of reaction per dose administered being almost identical–-8% for each dose administered. Eleven of 31 patients (35%) experienced anaphylactic reactions, 9/27 (33%) with E. coli and 3/10 (30%) with Erwinia asparaginase, with one patient suffering anaphy-laxis to both preparations. A marked increase in the percentage of patients having reactions occurred after the fourth dose of either preparation, with the incidence per dose increasing from 3.3% with the first dose to 32% on the fifth and subsequent doses. Rationale for an antibody-mediated allergic reaction is presented to explain the data.This publication has 14 references indexed in Scilit:
- Therapy with Erwinia l-asparaginase in children with acute leukemia after anaphylaxis to E. coli l-asparaginaseCancer, 1974
- Toxicity of L-asparaginase in children with advanced leukemiaCancer, 1972
- A comparison ofl-asparaginase fromErwinia aroideae and fromEscherichia coli: Biochemical and biological propertiesCellular and Molecular Life Sciences, 1971
- L-asparaginase therapy in children with advanced leukemiaThe Southwest cancer chemotherapy study groupCancer, 1971
- Comparison of daily versus weeklyl-asparaginase for the treatment of childhood acute leukemiaThe Journal of Pediatrics, 1970
- L-AsparaginaseAnnual Review of Medicine, 1970
- The Place of the L-Asparaginase in the Treatment of Acute LeukemiasPublished by Springer Nature ,1970
- Clinical Experience with L-AsparaginasePublished by Springer Nature ,1970
- L-AsparaginaseNew England Journal of Medicine, 1969
- A NEW L-ASPARAGINASE WITH ANTITUMOUR ACTIVITYThe Lancet, 1968